Sierra Oncology brings on former Aimmune CEO to the helm; Flagship woos ex-Novartis exec Fabrice Chouraqui
→ Momelotinib-focused Sierra Oncology, which launched a Phase III trial in November for myelofibrosis patients, has made Stephen Dilly its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
